| Product Name | Tamoxifen-13C6 |
| Product Code | DA-T005-u |
| Chemical name | Tamoxifen-13C6 |
| Synonyms | (Z)-2-[4-[1-(phenyl-13C6)-2-phenyl-1-butenyl]phenoxy]-N,N-dimethylethanamine; ICI 47699-13C6; Mammaton-13C6; Novaldex-13C6; Tamoxifen-13C6; Z-Tamoxifen-13C6;trans-Tamoxifen-13C6; |
| Impurity | NA |
| CAS Number | 1346606-38-9 |
| Alternate CAS # | NA |
| Molecular form | C2013C6H29NO |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 377.47 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | aromatics,stable isotopes,pharmaceutical standards,intermediates,fine chemicals,protein kinase inhibitors and activators |
| Boiling Point | NA |
| Applications | A labelled Tamoxifen; a selective estrogen response modifier (SERM), protein kinase C inhibitor and anti-angiogenetic factor. Tamoxifen is a prodrug that is metabolized to active metabolites 4-hydroxytamoxifen (4-OHT) and endoxifen by cytochrome P450 isoforms CYP2D6 and CYP3A4. In breast cancer, the gene repressor activity of tamoxifen against ERBB2 is dependent upon PAX2. Blocks estradiol-stimulated VEGF production in breast tumor cells. Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
